The increase in price target from $10 to $13 by Truist Securities indicates a positive outlook on the stock's future performance, despite the Hold rating. This adjustment suggests that the analyst sees potential for growth or improvement in Hims & Hers Health's stock value, which could lead to a positive short-term impact on the stock price.